A 12-month, Open-labelled, Randomised, Parallel-group, Multi-centre, Interventional Trial to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone (hGH) (Norditropin; Nordilet) Therapy on Height Velocity (Ht-V) in Patients With Idiopathic Short Stature in Korea

Trial Profile

A 12-month, Open-labelled, Randomised, Parallel-group, Multi-centre, Interventional Trial to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone (hGH) (Norditropin; Nordilet) Therapy on Height Velocity (Ht-V) in Patients With Idiopathic Short Stature in Korea

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Somatropin (Primary)
  • Indications Short stature
  • Focus Registrational; Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 04 Apr 2016 Primary endpoint (Height velocity (Ht-V) after 6 months treatment) has been met, according to results presented at The 98th Annual Meeting of the Endocrine Society.
    • 04 Apr 2016 Results assessing efficacy of recombinant human growth hormone (hGH) (Norditropin; Nordilet) presented at The 98th Annual Meeting of the Endocrine Society.
    • 18 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top